These findings suggest that CMPD1 is not only effective in inhibiting tumor growth in both in vitro and in vivo models but also appears to be more potent and safer than PTX, a standard chemotherapeutic agent for breast cancer treatment. This evidence concerns the gene SOX9 and breast carcinoma.